- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02201381
Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer (METRICS)
A Non Randomised, Non Blinded Real World Trial of the Safety, Tolerability and Effectiveness of Metabolic Medicines for the Treatment of Cancer Compared Against Matched Controls
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
*This study has been designed to collect data prospectively and to retrospectively analyse data on the metabolic treatments within the cancer clinic. The retrospective study is ongoing, while the prospective study has not yet started.*
This is a real world study since this gives the best opportunity to properly examine the effect of multi-drug regimens in representative populations. Including a standard of care arm is inappropriate, in a population in which that standard of care has already been shown to be ineffective or intolerable.
Patients will be sent to the study clinic directly by their Health Care Professionals ("HCP's") .
The study will consist of a pre-screening visit to determine eligibility for inclusion into the study, an initiation visit and then a follow up visit every three months thereafter. If required, unscheduled visits may take place. Day 0 (baseline) for each patient will be the initiation visit when study treatment is started.
Prior to conducting any study-related procedures, subjects will provide written informed consent, eligibility will be assessed, a medical history and past medical records will be taken and vital signs will be measured. These records will include the stage of their disease, response to previous cancer therapy, their prior and current medications and any specific regimen they are currently on for their cancer. If prior medical records do not contain sufficient information to determine a baseline for the patient, additional blood tests and scans will be undertaken as appropriate.
Patients will be monitored quarterly thereafter when blood tests (e.g. safety parameters, glucose, cholesterol, immune response and cancer markers where applicable) and scans (where applicable) will be taken.
All patients will be on the same drug regimen (see below) at the same doses throughout the study. All patients will be followed up until they choose to leave the study, or death.
Data from all patients recruited to the study will be analysed using an Intention-to-treat (ITT) philosophy, so data will be included in the primary analysis irrespective of whether the dose regimen was followed throughout the study. If appropriate, and numbers allow, analysis will also be conducted on the Per Protocol population, comprising those patients who adhere to the regimen as prescribed.
Survival analysis methods will be used to estimate the Overall survival associated with the study regimen for each type of cancer. These estimates will be interpreted in the light of data obtained from the literature, and from eliciting expert opinion. Bayesian methods may be used where appropriate.
Tumour response, where applicable, will be summarised in tables and graphs. Estimates of response rates will be presented for each cancer type with confidence intervals.
The relationship between changes in biochemistry values (glucose, lipids) and efficacy outcomes (Progression Free Survival (PFS), Overall Survival (OS) and HRQoL) will be investigated graphically, or using other methods as appropriate.
Further exploratory analysis to investigate the effects of other factors such as age , ethnic backgrounds , cancer stage, and response to prior therapy, will also be conducted in order to try and characterise the profile of patients most likely to benefit from the study regimen.
The characteristics of patients on the regimen and those who do not stay on the regimen, for whatever reason, will be summarised to see whether there is any observed bias. If appropriate, methods will be used to adjust for any observed bias, for example using propensity scores. OS can then be assessed adjusted for this to try and mitigate for any possible risk of bias which can occur in uncontrolled studies. Furthermore, by enrolling all eligible patients over a specified time frame, it is hoped that the risk of bias should be further reduced. In addition, a large number of patients are expected to participate in the study.
Study Type
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
London, United Kingdom, W1G 9PP
- Care Oncology Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria
- Male or female 18-85 years old;
- Diagnosed with cancer and have had such diagnosis confirmed by scan, blood markers and/or biopsy;
- Is receiving or will shortly receive standard of care therapy or has completed standard of care treatment; and
- Signed and dated written informed consent from the participant or LAR.
Exclusion Criteria:
- Pregnant or lactating females or females who are planning a pregnancy during the course of the study;
- Major organ failure, renal, lung and liver failure;
- Participants having active liver disease or unexplained persistent elevation of serum transaminases > 3 times the upper limit of normal;
- Participants with diabetic ketoacidosis or diabetic pre-coma;
- Participants with a creatinine clearance < 60mL/min;
- History of cardiac or respiratory failure;
- History of recent myocardial infarction;
- Ileum, colon or stomach part or full removal rendering them unable to take the study medicines;
- Unable to eat or keep food or medicines down or is being fed intravenously;
- Is too frail and weak to withstand the study medicines in the opinion of the study doctor;
- Is Unlikely to survive more than 1 month under standard of care, in the opinion of the study doctor
- Hypersensitivity to any of the treatment drugs or excipients;
- If the patient is on any medicines contraindicated with the study medicines (see Appendix 3);
- Mentally incapacitated and no guardian able to sign on patients Clinical study protocol, version 5.0 METRICS TRIAL, Metabolic Cancer 001 5th Apr 2016 Confidential Page 5 of 65 behalf;
- History or presence of alcohol or substance abuse;
- Participation in a clinical trial of an investigational medicinal product that is viewed by the Study Physician to be a significant risk to the participant's safety;
- Direct employee of the study site.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Metabolic Treatment
Subjects will take the following treatments and have their data collected from their medical records every 3 months.
|
While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: up to 5 years
|
Overall survival for all cancer types and for each cancer type (years and months)
|
up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in primary tumour size cancer types and by cancer type.
Time Frame: up to 5 years
|
Tumour size for all cancer types and for each cancer type.
Units of size vary depending on cancer type.
|
up to 5 years
|
Change in tumour spread (metastasis)
Time Frame: up to 5 years
|
Tumour spread (metastasized) to other tissues/organs, for all cancer types and for each cancer type.
This is measured as either 0 for no spread or 1 for confirmed spread.
|
up to 5 years
|
Change in tumour number
Time Frame: up to 5 years
|
Tumour number for all cancer types and for each cancer type
|
up to 5 years
|
Change in cancer biomarkers (blood, urine or biopsy)
Time Frame: up to 5 years
|
Cancer biomarkers for all cancer types and for each cancer type.
Units of measurement vary depending on the cancer type.
When biomarkers, either alone or in combination with other biomarkers, are raised above normal they are seen as predictive of cancer of progression.
If returned to normal are indicative of treatment response.
|
up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment related adverse events
Time Frame: 5 years
|
Adverse events reported by the subject or their HCP. • Quarterly assessment of routine laboratory tests |
5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Samir Agrawal, MRCP FRCPath, Care Oncology Clinic
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Breast Cancer
- Cancer
- Metformin
- AML
- Pancreatic Cancer
- Metastatic
- Ovarian Cancer
- Statins
- Triple Negative Breast Cancer
- Brain Cancer
- CML
- Colon Cancer
- Mebendazole
- Ibuprofen
- Metabolic
- Doxycycline
- Metabolism
- Real World
- Cancer Treatments
- Cancer Palliative Care
- Existing Medicines
- Licensed Medicines
- Prostrate Cancer
- Leukemea
Additional Relevant MeSH Terms
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antimetabolites
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Anti-Bacterial Agents
- Antiprotozoal Agents
- Antiparasitic Agents
- Antimalarials
- Antinematodal Agents
- Anthelmintics
- Atorvastatin
- Metformin
- Doxycycline
- Mebendazole
Other Study ID Numbers
- Metabolic Cancer 001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cancer
-
University of Michigan Rogel Cancer CenterRecruitingCancer Liver | Cancer Brain | Cancer Head &Neck | Cancer PelvisUnited States
-
Cellworks Group Inc.RecruitingCancer | Relapsed Cancer | Refractory CancerUnited States
-
UNC Lineberger Comprehensive Cancer CenterHyundai Hope On WheelsRecruitingCancer | Pediatric Cancer | Survivorship | Cancer MetastaticUnited States
-
Vanderbilt-Ingram Cancer CenterNational Institutes of Health (NIH)Active, not recruitingAdvanced Cancer | Relapsed Cancer | Refractory CancerUnited States
-
MiRXES Pte LtdRecruitingBreast Cancer | Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Prostate Cancer | Thoracic Cancer | Liver CancerSingapore
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IV Gastric Cancer | Stage IVA Colorectal Cancer | Stage IVA Pancreatic Cancer | Stage IVB Colorectal Cancer | Stage IVB Pancreatic Cancer | Stage IIIA Gastric Cancer | Stage IIIB Gastric Cancer | Stage IIIC Gastric... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedStage I Breast Cancer | Stage I Uterine Corpus Cancer | Stage II Uterine Corpus Cancer | Stage III Uterine Corpus Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage... and other conditionsUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompletedGastric Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Colon Cancer | Hepatobiliary CancerUnited States
-
Johns Hopkins UniversityNational Cancer Institute (NCI); National Institute on Minority Health and...Enrolling by invitationCancer | Advanced Cancer | End Stage Cancer | MalignancyUnited States
-
University of California, San FranciscoBristol-Myers Squibb; PfizerTerminatedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Metastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal... and other conditionsUnited States
Clinical Trials on Metabolic treatment
-
Pennington Biomedical Research CenterEnrolling by invitationObesity | Metabolic SyndromeUnited States
-
Waikato HospitalWellington HospitalRecruitingGlioblastomaNew Zealand
-
University of MichiganAmerican Diabetes AssociationCompletedMetabolic SyndromeUnited States
-
Icahn School of Medicine at Mount SinaiRecruiting
-
University Hospital, Strasbourg, FranceRecruiting
-
Emory UniversityRecruiting
-
University Hospital, Clermont-FerrandRegional Program for Clinical Research 2009 (PHRC 2009); Thermal Institution...Unknown
-
Stanford UniversityStanford Cancer CouncilTerminatedRectal CancerUnited States
-
University of Missouri-ColumbiaUniversity of WashingtonRecruiting
-
Hospital Universitario Doctor PesetUnknownDiabetes Mellitus | Sleeve Gastrectomy | Metabolic Surgery | BPGYSpain